Study
Overview The TRACK
trial will evaluate whether a small dose of rivaroxaban, a
blood-thinning medication, would reduce cardiovascular death or
major cardiovascular events in patients with advanced stages of
chronic kidney disease.
There has been a change to
Exclusion Criteria #1 which currently states in the protocol: 'Mechanical/prosthetic
heart valve'. Please see clarification in red
below.
This update to the Exclusion Criteria will be part of the next
protocol amendment.
2. Collection of COVID-19 vaccination status
Going forward, COVID-19 vaccination
status data will be collected in the Concomitant Medication form in
the eCRF.
New page for Patient
Alert Card and Cheat Sheet which contains guides for
Eligibility and SAE reporting
New online training
videos
IBM Training
Database Passwords
The passwords for the TRACK training database in IBM have been
updated.
Upon signing in, please remember to untick the 'Show Live Studies'
checkbox so that the 'TRACK Training' database can appear.
